Pieris Pharmaceuticals (NASDAQ:PIRS) Given New $12.00 Price Target at HC Wainwright

Pieris Pharmaceuticals (NASDAQ:PIRS) had its price target boosted by equities research analysts at HC Wainwright from $9.00 to $12.00 in a report issued on Tuesday, January 16th, Marketbeat Ratings reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 39.70% from the company’s previous close.

Several other equities research analysts also recently weighed in on PIRS. BidaskClub raised Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. ValuEngine downgraded Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $10.00.

Pieris Pharmaceuticals (PIRS) traded up $1.44 during mid-day trading on Tuesday, hitting $8.59. 2,012,123 shares of the company were exchanged, compared to its average volume of 721,830. The stock has a market capitalization of $384.78, a price-to-earnings ratio of -11.61 and a beta of 1.57. Pieris Pharmaceuticals has a 12-month low of $1.88 and a 12-month high of $8.79.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. The company had revenue of $3.93 million for the quarter, compared to analyst estimates of $1.52 million. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 221.93%. Pieris Pharmaceuticals’s quarterly revenue was up 400.3% compared to the same quarter last year. equities analysts predict that Pieris Pharmaceuticals will post -0.62 earnings per share for the current year.

In other news, major shareholder Orbimed Advisors Llc sold 1,709,620 shares of the firm’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $7.35, for a total value of $12,565,707.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 4.05% of the stock is currently owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Voya Investment Management LLC purchased a new stake in Pieris Pharmaceuticals during the 2nd quarter worth about $100,000. Wells Fargo & Company MN purchased a new stake in Pieris Pharmaceuticals in the 3rd quarter valued at about $105,000. Cetera Advisor Networks LLC purchased a new stake in Pieris Pharmaceuticals in the 4th quarter valued at about $124,000. Bank of Montreal Can purchased a new stake in Pieris Pharmaceuticals in the 4th quarter valued at about $144,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Pieris Pharmaceuticals by 1,106.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 29,150 shares during the period. Hedge funds and other institutional investors own 50.78% of the company’s stock.

WARNING: This report was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://ledgergazette.com/2018/02/12/pieris-pharmaceuticals-pirs-price-target-raised-to-12-00-at-hc-wainwright.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply